Cerence Inc

CRNC remains in a Stage 2 advancing regime undergoing a corrective reset. The medium-term bias stays bullish on higher-highs/higher-lows intact above the rising 50 DMA, while short-term price is being rejected by the flattened 9/21 EMA zone. Execution is deferred (Stalk), with focus on pullbacks into 50 DMA support or upon reclaim and acceptance of the 9/21 EMAs.

• ↑Q2 revenue $64.2M beat expectations; full-year guidance lifted to $305–320M.
• ↑Free cash flow of $13.6M in Q2 underpins financial discipline.
• ↓Gross margin declined 300bps YoY to 74%, indicating margin squeeze.